View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Aug. 26 (HealthDay News) -- Nucynta ER (tapentadol extended release) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe chronic pain in adults, maker Janssen Pharmaceuticals said.
The extended-release version of the opioid drug is taken twice daily. The original formulation of Nucynta was approved by the FDA in 2008.
Almost one-third of Americans will have chronic pain at some point in their lives, making it the most common form of long-term disability, the drug maker said.
In clinical testing of Nucynta, the most common side effects were nausea, constipation, headache and dizziness. People taking the drug must not consume alcohol or any medications that contain alcohol, Janssen said in a news release.
Janssen is a unit of Johnson & Johnson, New Brunswick, N.J.
Medline Plus has more about this drug.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top